Serum IgG antibodies against Helicobacter pylori low molecular weight antigens 50kDa, 30kDa and Urease A 26 kDa, along with vacuolating cytotoxin A are associated with the outcome of the infection

Nebojša Manojlović; Ivana Tufegdžić; Elizabeta Ristanović; Dubravko Bokonjić

doi:10.2298/VSP170928086M

Nebojša Manojlović Military Medical Academy, *Clinic for Gastroenterology and Hepatology
Ivana Tufegdžić Military Medical Academy, Institute for Pathology
Elizabeta Ristanović Military Medical Academy, Institute for Microbiology; University of Defence, Faculty of Medicine of Military Medical Academy
Dubravko Bokonjić Military Medical Academy, National Poison Control Center; University of Defence, Faculty of Medicine of Military Medical Academy

DOI: https://doi.org/10.2298/VSP170928086M

Keywords: helicobacter pylori;, antigens;, biomarkers;, stomach ulcer;, stomach neoplasms;, duodenal ulcer;, duodenal neoplasms

Abstract

Background/Aim. We designed and conducted this study due to the fact that results of the previous studies about seroreactivity to low-molecular-weight Helicobacter pylori antigens, cytotoxin-associated gene A (CagA), vacuolating cytotoxin A (VacA) in patients with gastric cancer and peptic ulcer were conflicting. Methods. The Western blot test was performed in 123 patients, 31 with gastric cancer, 31 with duodenal ulcer, 31 with gastric ulcer, 30 with gastritis and functional dyspepsia in order to determine IgG antibodies to H. pylori antigens (CagA, VacA, Heat shock protein 60kDa, Urease B 66 kDa, Flagellin 55kDa, 50kDa, 30 kDa, Urease A 26 kDa, 24 kDa). In this study we analyzed: seroreactivity to H. pylori antigens between group with functional dyspepsia and others; between grades of different histopathological parameters of inflammation of antral and corporal mucosa and between antrum-predominant gastritis and corpus-predominant gastritis + pangastritis groups. Results. It was shown that seropositivity to 50 kDa antigen could be used as a biomarker for functional dyspepsia, seropositivity to 30 kDa antigen for antrum-predominant gastritis and H. pylori colonization in the antrum, to UreaseA26 kDa antigen for pangastritis and corpus-predominant gastritis and degree of inflammation in the corpus. Seropositivity to VacA was the biomarker for gastric cancer and peptic ulcer taken together and inflammation of antral mucosa. Seropositivity to CagA was associated with more intensive inflammation of antral and corporal mucosa, Urease B66 kDa with inflammation of corpus mucosa, but neither of them with specific outcome of H. pylori infection and topographic distribution of gastric inflammation. Conclusion. Serum IgG antibodies to H. pylori antigens 50kDa, and VacA may represent useful biomarkers for the specific outcome of H. pylori infection, while serum antibodies to 30 kDa and UreaseA26 kDa antigens might be used as specific biomarkers for different topographic distribution of inflammation in gastric mucosa.

References

Hooi KY, Lai YW, Khoon Ng W, Suen MY, Underwood EF, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastro¬en-terology 2017; 153(2): 420–9.

Chmiela M, Karwowska Z, Gonciarz W, Allushi B, Stączek P. Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol 2017; 23(9): 1521–40.

Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134(1): 306–23.

Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2: 59–69.

Cello JP. Helicobacter pylori and peptic ulcer disease. AJR Am J Roentgenol 1995; 164(2): 283–6.

Talley NJ, Quan C. Review article: Helicobacter pylori and nonulcer dyspepsia. Aliment Pharmacol Ther 2002; 16 Suppl 1: 58–65.

Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: When and How to Test for Helicobacter pylori Infection. Gastroenterol Res Pract 2016; 2016: 8463614.

Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis Biomed J 2016; 39(1): 14–23.

Li Q, Liu J, Gong Y, Yuan Y. Serum VacA antibody is associated with risks of peptic ulcer and gastric cancer: A meta-analysis. Microb Pathog 2016; 99: 220–8.

Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe 2014; 15(3): 306–16.

Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol 2015; 7(12): 455–65.

Zhao Z, Li Y, Liu S, Fu W. Serum Helicobacter pylori CagA antibody may not be used as a tumor marker for diagnosing gastric cancer in east Asian countries. Tumour Biol 2014; 35(12): 12217–24.

Shiesh SC, Sheu BS, Yang HB, Tsao HJ, Lin XZ. Serologic response to lower-molecular-weight proteins of H. pylori is related to clinical outcome of H. pylori infection in Taiwan. Dig Dis Sci 2000; 45(4): 781–8.

Mitchell HM, Hazell SL, Li YY, Hu PJ. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 1996; 91(9): 1785–8.

Lamarque D, Gilbert T, Roudaut-Thoraval F, Deforges L, Chaumette MT, Delchier JC. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Eur J Gastroenterol Hepatol 1999; 11(7): 721–6.

Kuo CH, Wu DC, Lu CY, Su YC, Yu FJ, Lee YC, et al. Low molecular weight protein of Helicobacter pylori and its relation to gastroduodenal diseases. Hepatogastroenterol 2003; 50(52): 897–901.

Karami N, Talebkhan Y, Saberi S, Esmaeili M, Oghalaie A, Abdirad A, et al. Seroreactivity to Helicobacter pylori antigens as a risk indicator of gastric cancer. Asian Pac J Cancer Prev 2013; 14(3): 1813–7.

Chomvarin C, Ottiwet O, Hahnvajanawong C, Intapan PM, Wongwajana S. Seroreactivity to specific antigens of Helicobacter pylori infection is associated with an increased risk of the dyspeptic gastrointestinal diseases. Int J Infect Dis 2009; 13(5): 647–54.

Vilaichone RK, Mahachai V, Kositchaiwat C, Graham DY, Yamaoka Y. Relation between seroreactivity to low-molecular-weight Helicobacter pylori-specific antigens and disease presentation. Clin Diagn Lab Immunol 2003; 10(6): 1025–8.

Filipec Kanizaj T, Katicić M, Presecki V, Gasparov S, Colić Cvrlje V, Kolarić B, et al. Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases-cross-sectional study. Croat Med J 2009; 50(2): 124–32.

Yang KC, Chu A, Liao CS, Lin YM, Wang GM. Evaluation of the role of H. pylori infection in pathogenesis of gastric cancer by immunoblot assay. World J Gastroenterol 2006; 12(43): 7029–32.

Schumann C, Triantafilou K, Rasche FM, Möricke A, Vogt K, Triantafilou M, et al. Serum antibody positivity for distinct Helicobacter pylori antigens in benign and malignant gastroduodenal disease. Int J Med Microbiol 2006; 296(4–5): 223–8.

Janulaityte-Günther D, Kupcinskas L, Pavilonis A, Valuckas K, Wadström T, Andersen LP. Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer. FEMS Immunol Med Microbiol 2007; 50(2): 220–5.

Mitchell HM, Hazell SL, Li YY, Hu PJ. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 1996; 91(9): 1785–8.

Lamarque D, Gilbert T, Roudot-Thoraval F, Deforges L, Chaumette MT, Delchier JC. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Eur J Gastroenterol Hepatol 1999; 11(7): 721–6.

Aucher P, Petit ML, Mannant PR, Pezennec L, Babin P, Fauchere JL. Use of immunoblot assay to define serum antibody patterns associated with Helicobacter pylori infection and with H. pylori-related ulcers. J Clin Microbiol 1998; 36(4): 931–6.

Vorobjova T, Ananieva O, Maaroos H, Sipponen P, Villako K, Utt M, et al. Seropositivity to Helicobacter pylori heat shock protein 60 is strongly associated with intensity of chronic inflammation, particularly in antrum mucosa: an extension of an 18-year follow-up study of chronic gastritis in Saaremaa, Estonia. FEMS Immunol Med Microbiol 2001; 30(2): 143–9.

Barton SG, Winrow VR, Rampton DS, Crabtree JE, Beales IL, Calam J. Circulating antibodies to the 60-kD heat shock protein (hsp) family in patients with Helicobacter pylori infection. Clin Exp Immunol 1998; 112(3): 490–4.

Güdücüoğlu H, Berktaş M, Bozkurt H, Toka Ozer T, Bulut G, Oztürk O, et al. Evaluation of Western Blot method for the detection of antibodies to Helicobacter pylori antigens in patients with gastric carcinoma and cases with epigastric complaints. Microbiol Bull 2010; 44(1): 21–8.

Iaquinto G, Todisco A, Giardullo N, D'Onofrio V, Pasquale L, De Luca A, et al. Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Dig Liver Dis 2000; 32(5): 378–83.

Hassan TMM, Al-Najjar SI, Al-Zahrani IH, Alanazi FIB, Alotibi MG. Helicobacter pylori chronic gastritis updated Sydney grading in relation to endoscopic findings and H. pylori IgG antibody: diagnostic methods. J Micros Ultrastruct 2016; 4(4): 167–74.

Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol 2015; 50(6): 657–67.

Andersen LP, Gaarslev K. IgG subclass antibodies against Helicobacter pylori heat-stable antigens in normal persons and in dyspeptic patients. APMIS 1992; 100(8): 747–51.

Piñeros DM, Riveros SC, Marin JD, Ricardo O, Díaz OO. Helicobacter pylori in gastric cancer and peptic ulcer disease in a Colombian population. Strain heterogeneity and antibody profiles. Helicobacter 2001; 6(3): 199–206.

Sokic-Milutinovic A, Wex T, Todorovic V, Milosavljevic T, Malfert-heiner P. Anti-CagA and anti-VacA antibodies in Helicobacter pylori-infected patients with and without peptic ulcer disease in Serbia and Montenegro. Scand J Gastroenterol 2004; 39(3): 222–6.